Regression and Stabilization of Coronary Atheroma with Lipid-Lowering Therapy: The PACMAN-AMI Trial
According to the PACMAN-AMI trial, one-third of post-AMI patients receiving high-intensity lipid-lowering therapy showed a decrease in atheroma volume, a reduction in maxLCBI4mm, and increase in minimal fibrous capsule thickness, which were associated with treatment with alirocumab, higher baseline lipid content, and fewer cardiovascular events. Dr. Flavio G. Biccire of Bern University Hospital, Switzerland, and colleagues reported in the October 31 issue of the Journal of the American College of Cardiology.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
